Scinai Immunotherapeutics
SCNI
10 hedge funds and large institutions have $309K invested in Scinai Immunotherapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
11% more funds holding
Funds holding: 9 → 10 (+1)
0% less ownership
Funds ownership: 0% → 0% (-0%)
63% less capital invested
Capital invested by funds: $839K → $309K (-$530K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$18.9K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$6.04K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$233K |
| 2 |
Millennium Management
New York
|
-$55.3K |
| 3 |
VF
Virtu Financial
New York
|
-$23K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$8.65K |
| 5 |
Morgan Stanley
New York
|
-$138 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $269K | -$233K | -13,504 | -41% |
|
|
2
Millennium Management
New York
| $15.7K | -$55.3K | -3,202 | -73% |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $14.9K | +$18.9K | +1,092 | New |
|
|
4
RhumbLine Advisers
Boston,
Massachusetts
| $4.76K | +$6.04K | +350 | New |
|
|
5
Morgan Stanley
New York
| $3.08K | -$138 | -8 | -4% |
|
6
Credit Agricole
Montrouge Cedex,
France
| $598 | – | – | – |
|
|
7
UBS Group
Zurich,
Switzerland
| $431 | -$8.65K | -501 | -94% |
|
|
APC
8
Aspire Private Capital
Cornelius,
North Carolina
| $226 | – | – | – |
|
|
GRP
9
Global Retirement Partners
San Rafael,
California
| $71 | – | – | – |
|
10
Wells Fargo
San Francisco,
California
| $28 | – | – | – |
|
|
NC
11
NewSquare Capital
Newtown Square,
Pennsylvania
| $3 | – | – | – |
|
|
VF
12
Virtu Financial
New York
| – | -$23K | -1,051 | Closed |
|
SCNI Hedge Fund Activity: Q2 2023 in Review
10 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2023, worth a combined $309K — down 63% from $839K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new SCNI positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 4 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $18.9K. The largest seller was Sabby Management, cutting an estimated $233K.
- 10 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2023, up from 9 in Q1 2023.
- Funds reported $309K of Scinai Immunotherapeutics stock for Q2 2023, down 63% quarter-over-quarter.
- 2 funds opened new Scinai Immunotherapeutics positions in Q2 2023 and 1 closed out, a net change of +1 holder.
- The largest Scinai Immunotherapeutics buyer in Q2 2023 was Susquehanna International Group, an estimated $18.9K added.
- The largest Scinai Immunotherapeutics seller in Q2 2023 was Sabby Management, an estimated $233K sold.
Based on aggregated 13F filings for Q2 2023.